CA2199250A1 - Oestrogenes et hormone parathyroidienne utiles pour traiter l'osteoporose - Google Patents

Oestrogenes et hormone parathyroidienne utiles pour traiter l'osteoporose

Info

Publication number
CA2199250A1
CA2199250A1 CA002199250A CA2199250A CA2199250A1 CA 2199250 A1 CA2199250 A1 CA 2199250A1 CA 002199250 A CA002199250 A CA 002199250A CA 2199250 A CA2199250 A CA 2199250A CA 2199250 A1 CA2199250 A1 CA 2199250A1
Authority
CA
Canada
Prior art keywords
bone
osteoporosis
estrogen
parathyroid hormone
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002199250A
Other languages
English (en)
Inventor
John Althorp Bevan
Ann Dunbar Geddes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2199250A1 publication Critical patent/CA2199250A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Procédés de traitement destinés à un homme ou un animal atteint d'un dérèglement du métabolisme osseux, ces procédés consistant principalement à: (a) administrer au sujet une quantité efficace et sûre d'un composé antirésorptif pendant une période supérieure à 6 mois environ; et (b) administrer audit sujet une quantité efficace et sûre d'une hormone parathyroïdienne pendant une période de 3 à 12 mois environ.
CA002199250A 1994-09-09 1995-09-06 Oestrogenes et hormone parathyroidienne utiles pour traiter l'osteoporose Abandoned CA2199250A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30392694A 1994-09-09 1994-09-09
US303,926 1994-09-09

Publications (1)

Publication Number Publication Date
CA2199250A1 true CA2199250A1 (fr) 1996-03-14

Family

ID=23174293

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002199250A Abandoned CA2199250A1 (fr) 1994-09-09 1995-09-06 Oestrogenes et hormone parathyroidienne utiles pour traiter l'osteoporose

Country Status (8)

Country Link
EP (1) EP0804202A4 (fr)
JP (1) JP2001503728A (fr)
KR (1) KR970705397A (fr)
CN (1) CN1158569A (fr)
AU (1) AU3674895A (fr)
CA (1) CA2199250A1 (fr)
IL (1) IL115225A0 (fr)
WO (1) WO1996007416A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545635A (en) * 1995-05-23 1996-08-13 Eli Lilly And Company Inhibiting bone loss with equilenin
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
CA2628945A1 (fr) 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Parathormone de l'ours noir et procedes d'utilisation de la parathormone de l'ours noir
BR112012013725A2 (pt) 2009-12-07 2017-01-10 Univ Michigan Tech paratormônio de urso preto e métodos de usar o paratormônio de uso preto.
WO2015057836A2 (fr) * 2013-10-15 2015-04-23 The Trustees Of Columbia University In The City Of New York Hormone parathyroïdienne anabolique osseuse et analogues de protéine apparentée à l'hormone parathyroïdienne

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
TW303299B (fr) * 1993-07-22 1997-04-21 Lilly Co Eli

Also Published As

Publication number Publication date
AU3674895A (en) 1996-03-27
JP2001503728A (ja) 2001-03-21
EP0804202A1 (fr) 1997-11-05
WO1996007416A1 (fr) 1996-03-14
CN1158569A (zh) 1997-09-03
IL115225A0 (en) 1995-12-31
EP0804202A4 (fr) 1999-01-13
KR970705397A (ko) 1997-10-09

Similar Documents

Publication Publication Date Title
Hay Bone disease in cholestatic liver disease
Cosman et al. Parathyroid hormone treatment for osteoporosis
RU2112515C1 (ru) Способ лечения остеопороза
Vandeweghe et al. Short and long‐term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone‐deficient males
JP2531505B2 (ja) 骨質量増加用医薬複合剤の投与用キット
DE69201725T2 (de) Behandlungsmethoden für osteoporose.
CZ301017B6 (cs) Lécivo pro snížení rizika vertebrální nebo nevertebrální zlomeniny kosti u cloveka a rizika osteoporózy
Cunnane et al. STEROID–INDUCED OSTEOPOROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS
Combe et al. Equivalence of nasal spray and subcutaneous formulations of salmon calcitonin
Mitchell et al. Glucocorticoid-induced osteoporosis: mechanisms for bone loss; evaluation of strategies for prevention
EP1221966B1 (fr) Utilisation d'une hormone parathyroide pour reduire les risques de cancer
CA2199250A1 (fr) Oestrogenes et hormone parathyroidienne utiles pour traiter l'osteoporose
AU686458B2 (en) Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
WO1999004808A1 (fr) Medicaments dentaires contenant de la pth
Cascella et al. Effects of neridronate treatment in elderly women with osteoporosis
AU686019B2 (en) Phosphonates and parathyroid hormone for osteoporosis
JPH0873376A (ja) 骨粗鬆症治療薬
Manuele et al. The teriparatide in the treatment of severe senile osteoporosis
Zahid et al. Efficacy of Bisphosphonates and Recombinant Parathyroid Hormone in Treatment of Osteoporosis in Pakistan
Seymour et al. Prospects for treating osteoporosis in older people
Rittinghaus et al. The concept and treatment of osteoporosis
Dequeker Joint and musculoskeletal
US20160339063A1 (en) Composition for preventing and healing compromised bone and a method of making same
JPH1192395A (ja) Ｐｔｈを含有する歯科治療剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued